Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. Jan 13, 2025HRS9531 is being developed globally (ex-Greater China) by Kailera Therapeutics as KAI-9531. About Hengrui Pharma Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative global pharmaceutical company focused on unmet clinical needs, with a strong track record of scientific and technological innovation. Hengrui Pharma has set ...
  2. finance.yahoo.com

    Jan 13, 2025Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531 Kailera Therapeutics, Inc ...
  3. marketscreener.com

    Jan 13, 2025Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Kailera Therapeutics, Inc. (Kailera), announced positive topline data from the 8 mg dose of Hengrui Pharma?s Phase 2 clinical trial (HRS9531-203) of HRS9531, a GLP-1/GIP receptor dual agonist, in individuals living with obesity or overweight.
  4. patientcareonline.com

    Jan 15, 2025Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced compelling topline results from the phase 2 trial (HRS9531-203) evaluating the efficacy and safety of HRS9531, a novel dual glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP) agonist, in individuals with overweight or obesity. The findings, released on January 13, 2025, underscore the drug's potential ...
  5. fiercebiotech.com

    Jan 13, 2025Kailera and Hengrui Pharma previously showed the promise of HRS9531 in a phase 2 study that tested doses of up to 6 mg for 24 weeks. Placebo-adjusted mean weight loss in that trial topped out at ...
  6. Kailera's injectable and oral therapies are licensed from Jiangsu Hengrui Pharmaceuticals, a leading global pharmaceutical company. ... News. January 13, 2025. Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531.
  7. bariatricnews.net

    Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced positive topline data from the 8mg dose of Hengrui Pharma's Phase 2 clinical trial (HRS9531-203) of HRS9531, a GLP-1/GIP receptor dual agonist, in individuals living with obesity or overweight. HRS9531 is a novel injectable GLP-1/GIP receptor dual agonist formulated as an injectable peptide in clinical development for ...
  8. biospace.com

    Jan 13, 2025HRS9531 is being developed globally (ex-Greater China) by Kailera Therapeutics as KAI-9531. About Hengrui Pharma Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative global pharmaceutical company focused on unmet clinical needs, with a strong track record of scientific and technological innovation. Hengrui Pharma has set ...
  9. chinabiotoday.com

    Oct 1, 2024Kailera Therapeutics launched with a four-drug pipeline aimed at the very crowded target of obesity. The company was formed by four US venture capital companies who funded the startup in a $400 million Series A round. In May, Jiangsu Hengrui announced a $6 billion deal, heavily backloaded, with Kailera, then known as Hercules. Hengrui also received a 19.9% share of Kailera as part of the deal.

    Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX